We have located links that may give you full text access.
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Recurrence of sebaceous carcinoma of the eyelid after radiation therapy.
American Journal of Ophthalmology 1983 July
Sebaceous carcinoma originating in the meibomian gland recurred in six patients (four women, 61, 68, 71, and 88 years old, and two men, 52 and 65 years old) who had undergone radiation therapy. The patients had received radiation dosages ranging from 3,300 to 11,900 rads. The tumors recurred two months to two years after treatment. All six patients then underwent surgical excision of the tumors and have remained tumor-free for follow-up periods of as long as 42 months. These data indicated that radiation therapy of sebaceous carcinoma of the eyelid should be considered palliative rather than curative.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app